Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can read like a graduate textbook—especially when Acrivon Therapeutics packs its 10-K with proteomics jargon, trial protocols, and liquidity tables. If you’re searching “Acrivon Therapeutics SEC filings explained simply” or wondering how platinum-resistant ovarian cancer data affects the balance sheet, you’re in the right place. Stock Titan’s AI dissects every page the moment it hits EDGAR, so you spend minutes—not hours—finding what matters.
Need to track “Acrivon Therapeutics insider trading Form 4 transactions” before the next readout? Our dashboard streams Form 4 insider transactions in real time, flags option exercises, and links them to upcoming milestones disclosed in 8-Ks. Curious about cash runway? The quarterly earnings report 10-Q filing is paired with plain-English summaries that spotlight R&D spend, burn rate, and AP3 platform progress. We also map risk-factor changes between annual report 10-K filings, highlight any shelf-registration clues in S-3s, and surface board votes from the latest proxy statement on executive compensation.
Whether you’re parsing an “Acrivon Therapeutics earnings report filing analysis,” monitoring “Acrivon Therapeutics executive stock transactions Form 4,” or decoding an “Acrivon Therapeutics 8-K material events explained,” Stock Titan delivers comprehensive coverage. Our AI-powered summaries translate dense pathway diagrams into actionable insights, while expert commentary points out dilution risk and regulatory catalysts. Set custom alerts to know the second a new study start appears, compare segment performance across periods, and keep a pulse on WEE1/PKMYT1 clinical updates. All ACRV filings, all in one place, always up to date.
Acrivon Therapeutics (ACRV) reported Q3 2025 results, highlighting continued investment in its precision oncology programs. The company posted a net loss of
For the nine months ended September 30, net loss was
Pipeline progress continued. The registrational‑intent Phase 2 trial of ACR‑368 in endometrial cancer previously reported a 35% confirmed ORR and 80% tumor shrinkage in OncoSignature‑positive patients. The ACR‑368 OncoSignature test has FDA Breakthrough Device designation, and ACR‑368 holds Fast Track status. ACR‑2316, a WEE1/PKMYT1 inhibitor, is in Phase 1 with initial signs of activity, including a confirmed partial response at dose level 3. As of
Acrivon Therapeutics, Inc. furnished an 8‑K announcing it issued a press release covering financial results for the quarter ended September 30, 2025, and business updates. The press release is included as Exhibit 99.1 dated November 13, 2025.
The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference into other SEC filings.
Acrivon Therapeutics (ACRV) insider activity: The Chief Legal Officer reported a routine tax-withholding event tied to restricted stock unit vesting. On 10/17/2025, a Form 4 shows transaction code F, where 558 shares of common stock were withheld by the issuer at $1.81 to satisfy mandatory taxes. After this administrative transaction, the officer directly beneficially owns 34,739 shares.
Mirza Mansoor Raza, the company Chief Medical Officer, reported acquiring 225,000 stock options in Acrivon Therapeutics, Inc. (ACRV) on 10/01/2025. The options carry an exercise price of $1.81 and are reported as acquired (Transaction Code A), leaving the reporting person with 225,000 derivative securities beneficially owned following the transaction. The filing states vesting terms: 25% vests on November 1, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a non-derivative disposition on 10/01/2025. The filing shows 284 shares of common stock were disposed at a price of $1.81 per share. The form states the shares were withheld by the issuer to satisfy mandatory tax withholding upon the vesting of restricted stock units. After the reported transaction, Ms. Miller beneficially owns 35,297 shares, held directly. The Form 4 was signed by attorney-in-fact Adam D. Levy on 10/03/2025.
Acrivon Therapeutics insiders reported an internal share disposition related to restricted stock unit vesting. On 08/21/2025, President and CEO Dr. Peter Blume-Jensen had 19,905 common shares dispositioned at $1.32 per share; the filing states these shares were withheld by the issuer to satisfy mandatory tax withholding on vested restricted stock units. After the transaction Dr. Blume-Jensen is reported to beneficially own 2,126,440 shares (direct). The filing also shows 315,196 common shares held indirectly by EVP Dr. Kristina Masson. Both reporting persons are officers and directors and are spouses; each disclaims beneficial ownership of the other’s holdings except to the extent of pecuniary interest. The Form 4 is signed by an attorney-in-fact on behalf of both reporting persons.
Acrivon Therapeutics insider sale reported on Form 4. Katharine Peterson, Chief Accounting Officer, recorded a transaction dated 08/14/2025 disclosing a disposition of 99 shares of Acrivon Therapeutics common stock at a price of $1.39 per share. Following the reported sale, Ms. Peterson beneficially owns 4,221 shares, held directly. The filing states the 99 shares were withheld by the issuer to satisfy mandatory tax withholding upon RSU vesting and is signed by an attorney-in-fact on 08/18/2025.
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, Inc. (ACRV), reported a transaction on 08/14/2025 involving the company’s common stock. The filing shows 184 shares were disposed at a price of $1.39 per share.
The form states these shares were withheld by the issuer to satisfy a mandatory tax withholding obligation upon the vesting of restricted stock units. After the withholding, Ms. Miller beneficially owns 35,581 shares directly. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, reported a routine withholding of 403 shares of Common Stock on 08/14/2025 to satisfy mandatory tax withholding when restricted stock units vested. The withheld shares were disposed at a reported price of $1.39 per share. After the transaction, Mr. Gamelin beneficially owns 15,686 shares of ACRV common stock. The Form 4 was signed by an attorney-in-fact on 08/18/2025. The filing notes the withholding was to cover taxes tied to RSU vesting.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
